Company Overview of T2 Biosystems, Inc.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications; T2Candida panel for identifying pathogens associated with sepsis; and T2MR Platform, a magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. It is also developing T2Stat, an integrated instrument that provi...
101 Hartwell Avenue
Lexington, MA 02421
Founded in 2006
Key Executives for T2 Biosystems, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $350.0K
Chief Financial Officer and Chief Accounting Officer
Total Annual Compensation: $171.9K
Chief Operating Officer
Total Annual Compensation: $89.8K
Compensation as of Fiscal Year 2013.
T2 Biosystems, Inc. Key Developments
T2 Biosystems, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:00 AM
Feb 27 15
T2 Biosystems, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: John P. McDonough, Chief Executive Officer, President and Director.
T2 Biosystems, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014
Feb 17 15
T2 Biosystems, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $8,838,000 against $5,639,000 a year ago. Net loss was $9,076,000 against $6,374,000 a year ago. Net loss applicable to common stockholders was $9,076,000 or $0.45 per basic and diluted share against $8,284 million or $5.89 per diluted share a year ago.
For the year, the company reported loss from operations of $30,681,000 against $19,692,000 a year ago. Net loss was $31,390,000 against $20,610,000 a year ago. Net loss applicable to common stockholders was $35,960,000 or $4.15 per diluted share against $27,518,000 or $19.72 per diluted share a year ago.
T2 Biosystems, Inc. to Report Q4, 2014 Results on Feb 17, 2015
Feb 10 15
T2 Biosystems, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Feb 17, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|